Journal
ORAL ONCOLOGY
Volume 62, Issue -, Pages 78-84Publisher
ELSEVIER
DOI: 10.1016/j.oraloncology.2016.10.014
Keywords
Nasopharyngeal carcinoma; Locoregionally advanced; Neoadjuvant chemotherapy; Intensity-modulated radiotherapy; Prognosis
Categories
Funding
- Sun Yat-sen University Clinical Research 5010 Program [2012011]
- Science and Technology Project of Guangzhou City, China [14570006]
- Planned Science and Technology Project of Guangdong Province, China [2013B020400004]
Ask authors/readers for more resources
Objectives: The aim of this study is to optimize the cycle for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) receiving neoadjuvant chemotherapy (NCT) in the era of intensity-modulated radiotherapy (IMRT). Materials and methods: Data on 569 locoregionally advanced NPC patients treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance prognostic factors and match patients. Survival outcomes of matched patients between different NCT cycle groups were compared. Results: The median cycle of NCT was 2 (range, 2-4 cycles) for the whole cohort, and patients were therefore stratified as low cycle (= 2) and high cycle (> 2) groups. In total, 247 pairs of NPC patients were selected by PSM. Univariate analysis found no significantly prognostic difference between the low cycle and high cycle groups, and multivariate analysis did not establish NCT cycle as an independent factor. However, stratified analysis revealed patients in the low cycle group had better OS than those of patients in the high cycle group (92.4% vs. 80.8%, P = 0.029), and NCT was identified as an independent prognostic factor for OS in patients with N2-3 category (HR, 2.252; 95% CI, 1.024-4.953; P = 0.043). Conclusion: Two cycles of NCT may be enough and additional more cycles are not associated with improved survival outcomes for patients with locoregionally advanced NPC in the era of IMRT. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available